title: Head and neck presentations of B-NHL and B-AL in children/adolescents: experience of the LMB89 study.
abstract: OBJECTIVE
  Describe the epidemiology, clinical profiles and outcomes associated with head and neck (H&N) involvement in children/adolescents with B-cell non-Hodgkin lymphoma (B-NHL).
  
  
  METHODS
  Analysis of children/adolescents with H&N B-NHL prospectively enrolled in the SFOP LMB-89 trial (July 1989-June 1996).
  
  
  RESULTS
  One hundred and twelve of 561 patients (20%) had H&N involvement. The mean age of the patients was 8.4 years. Murphy staging differed between the H&N patients and the others (P < 0.0001): 9% versus 5% of the patients presented with stage I disease, 36% versus 11% presented with stage II disease, 12% versus 59% presented with stage III disease, 17% versus 10% with stage IV disease and 27% versus 16% with B-AL. Twenty-nine H&N patients (26%) had CNS involvement at diagnosis versus 8.5% in the group without H&N involvement (P < 0.0001). Patients were treated according to the LMB89 protocol: 3 H&N patients were allocated to group A, 70 to group B and 39 to group C. Ninety-seven percent of H&N patients achieved CR and event-free and overall survival at 4 years was 95.5% (5 deaths in patients with CNS disease). On multivariate analysis, EFS was significantly better in H&N patients than in non-H&N patients (P = 0.021), but not OS (P = 0.11).
  
  
  CONCLUSIONS
  The H&N site is the second most common location for B-NHL at diagnosis and is more frequently associated with disseminated disease and CNS involvement than other sites. However, outcomes are no worse for these patients than for the rest of the population.
authors: Pediatric Oncology Unit, Centre Oscar Lambret, Lille, France.
authors: Cyril
authors: C
authors: Lervat
authors: Anne
authors: A
authors: Auperin
authors: Catherine
authors: C
authors: Patte
authors: Françoise
authors: F
authors: Méchinaud
authors: Guy
authors: G
authors: Leverger
authors: Brigitte
authors: B
authors: Nelken
authors: Yves
authors: Y
authors: Bertrand
authors: Andre
authors: A
authors: Baruchel
authors: Carole
authors: C
authors: Coze
authors: Martine
authors: M
authors: Munzer
authors: M J Terrier
authors: MJ
authors: Lacombe
authors: Christophe
authors: C
authors: Bergeron
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005047:Etoposide / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006854:Hydrocortisone / Q000627:therapeutic use; D007223:Infant; D007770:L-Lactate Dehydrogenase / Q000097:blood; D002955:Leucovorin / Q000627:therapeutic use; D015448:Leukemia, B-Cell / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D009367:Neoplasm Staging; D011241:Prednisone / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D003561:Cytarabine; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D007770:L-Lactate Dehydrogenase; D002955:Leucovorin; D011241:Prednisone; D006854:Hydrocortisone; D008727:Methotrexate
keywords: B-cell non Hodgkin's lymphoma; chemotherapy; children; head and neck cancer